The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The company said the safety profile remained consistent with earlier studies and was considered manageable
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
